TICKERNERD
Menu
BIOBIOHealthcare · Medical Devices

BIO Stock Forecast: Bio-Rad Laboratories, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$382
+0.46% on the day

The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. hold a median 12-month price target of $330 — -13.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$10.2B
Ticker Nerd rank
92 / 100
Median analyst target
$330
Analysts covering
5
Total return, dividends reinvested
1W
+7.5%
1M
+21.4%
YTD
+26.0%
1Y
+25.7%
From 52W high
0.0%
From 52W low
+57.9%
$242
$382
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bio-Rad Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Issuance
88
Momentum
85
Volatility
84
Revisions
79
Quality
69
Accruals
65
Growth
43
Size
16

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (43): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Oct 25Jan 26Apr 26Jul 26BIOHigh $390Median $330Low $280

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
1 Buy3 Hold1 Sell
Low $280Median $330High $390

The green dot is the last close — the median target sits −13.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$370 → $390
5 Aug 2026CitigroupMaintainsNeutral$300 → $330
5 Aug 2026RBC CapitalMaintainsOutperform$320 → $370
5 Aug 2026Wells FargoMaintainsEqual-Weight$310 → $330
15 May 2026RBC CapitalReinstatesOutperform$320
1 May 2026Wells FargoMaintainsEqual-Weight—
7 Apr 2026CitigroupDowngradeNeutral—
16 Feb 2026Wells FargoMaintainsEqual-Weight—
30 Oct 2025CitigroupMaintainsBuy—
30 Oct 2025Wells FargoMaintainsEqual-Weight—
1 Aug 2025RBC CapitalMaintainsOutperform—
1 Aug 2025Wells FargoMaintainsEqual-Weight—
9 June 2025Wells FargoMaintainsEqual-Weight—
2 May 2025CitigroupMaintainsBuy—
2 May 2025RBC CapitalMaintainsOutperform—
2 May 2025UBSMaintainsBuy—
17 Apr 2025Wells FargoMaintainsEqual-Weight—
12 Feb 2025Wells FargoMaintainsEqual-Weight—
14 Jan 2025RBC CapitalReiteratesOutperform—
9 Dec 2024RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.4%
Analysts raising
4
Analysts cutting
0
Fundamentals

Bio-Rad Laboratories, Inc. (BIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
46.3×

Cheaper than 16% of US stocks

Price / sales
3.9×

Cheaper than 33% of US stocks

Price / book
1.4×

Cheaper than 59% of US stocks

EV / EBITDA
22.5×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
−0.1%

Higher than 27% of US stocks

Earnings growth (YoY)
16.9%

Higher than 56% of US stocks

Gross margin
53.1%

Higher than 66% of US stocks

Operating margin
11.2%

Higher than 66% of US stocks

Net margin
8.6%

Higher than 67% of US stocks

Returns & dividend
Return on equity
3.1%

Higher than 50% of US stocks

Return on assets
1.7%

Higher than 56% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BIOBio-Rad Laboratories, Inc.$10.2B
92
PODDInsulet Corp.$10.3B
90
GKOSGlaukos Corp.$10.9B
91
BRKRBruker Corp.$9.1B
84
GMEDGlobus Medical, Inc.$11.7B
96
PENPenumbra, Inc.$12.8B
76
ZBHZimmer Biomet Holdings, Inc.$20.0B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bio-Rad Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIO news & analysis

Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?

Zacks Investment Research · 21 Aug 2026neutral

Zacks discusses Bio-Rad Laboratories, noting that its digital PCR gains and recurring diagnostics base support growth, while a 40.2X forward price-to-earnings ratio and a muted 2026 outlook keep valuation risk in focus.

Why it matters — A BIO watcher would care because the report highlights both the company's growth drivers and the valuation concerns that could influence how its stock is viewed.

Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?

Zacks Investment Research · 20 Aug 2026neutral

Bio-Rad Laboratories' stock rose 19.1% over the past month, a rally supported by gains in digital PCR and steadier diagnostics demand. However, weak Life Science demand and a rich valuation pose potential challenges to sustaining the momentum.

Why it matters — The report highlights both the recent strength in BIO's share price and the mixed business conditions—growth in diagnostics offset by soft Life Science demand—that investors would watch when assessing its sustainability.

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Zacks Investment Research · 10 Aug 2026neutral

Zacks Investment Research highlights the importance of examining Bio-Rad's (BIO) international revenue trends when evaluating the stock, noting how these figures influence Wall Street forecasts.

Why it matters — BIO watchers would care because international revenue trends can affect analyst forecasts and expectations for the company's stock performance.

Bio-Rad Laboratories Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026negative

Bio-Rad Laboratories reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier and down 1.9% on a currency-neutral basis. The company said continued softness in academic research markets weighed on its Life Science segment.

Why it matters — The results signal ongoing weakness in academic research demand, which continues to pressure Bio-Rad's Life Science segment and overall top-line growth.

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published Bio-Rad Laboratories, Inc.'s Q2 2026 earnings call transcript, covering the company's quarterly financial results and management commentary.

Why it matters — A BIO watcher would be able to review management's discussion of the company's second-quarter 2026 performance and outlook.

FAQ

Frequently asked questions about BIO stock

What is the BIO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. have a median 12-month price target of $330, with estimates ranging from $280 to $390. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIO stock a buy right now?

Of the 5 analysts covering Bio-Rad Laboratories, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Rad Laboratories, Inc. 92 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIO?

As at 22 Aug 2026, Bio-Rad Laboratories, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will BIO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -13.6% from the last close, and Ticker Nerd's factor model ranks Bio-Rad Laboratories, Inc. 92 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIO stock forecast for 2030?

No analyst covering Bio-Rad Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $390 over the next 12 months.

How has BIO stock performed over the past year?

Bio-Rad Laboratories, Inc. returned +25.7% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bio-Rad Laboratories, Inc. do?

Bio-Rad Laboratories, Inc. develops, manufactures, and markets specialized products for the clinical diagnostics and life sciences markets.

What is the latest news on BIO?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?". Zacks discusses Bio-Rad Laboratories, noting that its digital PCR gains and recurring diagnostics base support growth, while a 40.2X forward price-to-earnings ratio and a muted 2026 outlook keep valuation risk in focus.

Company

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and markets specialized products for the clinical diagnostics and life sciences markets. In clinical diagnostics, the company provides test systems and quality control solutions for clinical laboratories. In life sciences, it produces instruments and reagents for research, biopharmaceutical production, and food testing, with a leadership position in digital PCR technology. The company operates globally across the Americas, Europe, and Asia, serving pharmaceutical companies, research institutions, clinical laboratories, and bioprocessing manufacturers. Bio-Rad also maintains a significant ownership stake in Sartorius, a supplier specializing in single-use bioprocessing technology. Founded in 1952 and headquartered in Hercules, California, the company operates a razor-and-blade business model in clinical diagnostics, combining durable instruments with recurring sales of consumable products and reagents to maintain steady revenue streams.

CEO Mr. Norman D. Schwartz · 7,450 employees · United States · https://www.bio-rad.com